Ligand Pharmaceuticals Incorporated (LGND)

102.40
NASDAQ
Prev Close 102.40
Day Low/High 0.00 / 0.00
52 Wk Low/High 79.66 / 139.79
Exchange NASDAQ
Shares Outstanding 20.85B
Market Cap 2.25B
Div & Yield N.A. (N.A)

Latest News

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Here are Friday's top research calls, including downgrades for FireEye and Teva Pharmaceuticals, and upgrades for Kraft Heinz and U.S. Steel.

Ligand Reports Second Quarter 2016 Financial Results

Ligand Reports Second Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2016, and provided an operating forecast and program updates.

Ligand Announces Multi-Program LTP Technology Licensing Agreement With Nucorion Pharmaceuticals

Ligand Announces Multi-Program LTP Technology Licensing Agreement With Nucorion Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand's LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc.

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a "perilous reversal" (up big yesterday but down big today) candidate

Ligand To Report Second Quarter Results On August 4th

Ligand To Report Second Quarter Results On August 4th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2016 financial results on August 4, 2016.

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

Shares of SAGE Therapeutics jumped after the company reported data from its SAGE-547 clinical trial for the treatment of severe postpartum depression.

Ligand Enters Into OmniAb® Platform License Agreement With Gilead Sciences

Ligand Enters Into OmniAb® Platform License Agreement With Gilead Sciences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc.

Ligand Receives $4 Million From Expansion Of Two OmniAb® License Agreements

Ligand Receives $4 Million From Expansion Of Two OmniAb® License Agreements

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand.

Insider Trading Alert - ATHN, LGND And ASPS Traded By Insiders

Insider Trading Alert - ATHN, LGND And ASPS Traded By Insiders

Stocks with insider trader activity include ATHN, LGND and ASPS

Ligand Reports First Quarter 2016 Financial Results

Ligand Reports First Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.

Ligand Acquires Portfolio Of Synthetic Royalty And Milestone Rights From CorMatrix® Cardiovascular For $17.5 Million

Ligand Acquires Portfolio Of Synthetic Royalty And Milestone Rights From CorMatrix® Cardiovascular For $17.5 Million

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to multiple programs owned by CorMatrix ®.

Ligand Announces First Quarter 2016 Earnings Reporting Date And Participation In Four Upcoming Investor Conferences

Ligand Announces First Quarter 2016 Earnings Reporting Date And Participation In Four Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces plans to report first quarter 2016 financial results prior to the opening of trading on May 4, 2016.

Revolade® Approved In EU As First In Class Therapy For Children Aged 1 Year And Above With Chronic ITP

Revolade® Approved In EU As First In Class Therapy For Children Aged 1 Year And Above With Chronic ITP

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the European Commission (EC) has approved Revolade® (eltrombopag), a Novartis product, for the treatment of pediatric (aged 1 year and above) chronic...

Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics

Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing innovative immuno-oncology therapies.

Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA™ (melphalan) For Injection

Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA™ (melphalan) For Injection

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Spectrum Pharmaceuticals, Inc.

Ligand Reports Fourth Quarter And Full Year 2015 Financial Results

Ligand Reports Fourth Quarter And Full Year 2015 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2015, and provided an operating forecast and program updates.

Ligand Enters Into OmniAb® Platform License Agreement With Tizona Therapeutics

Ligand Enters Into OmniAb® Platform License Agreement With Tizona Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Tizona Therapeutics, Inc.

Ligand To Report Fourth Quarter And Full Year 2015 Results On February 10th

Ligand To Report Fourth Quarter And Full Year 2015 Results On February 10th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2015 financial results on February 10, 2016.

These 2 Small-Cap Stocks Could Add Powerful Returns to Your Portfolio

These 2 Small-Cap Stocks Could Add Powerful Returns to Your Portfolio

The broader markets have been tanking, a fact that obscures the opportunities among selected small-cap rockets. We examine two of the most promising.

Ligand Enters Into OmniAb® Platform License Agreement With Emergent BioSolutions

Ligand Enters Into OmniAb® Platform License Agreement With Emergent BioSolutions

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Emergent BioSolutions Inc.

Ligand To Acquire OMT, Inc., A Leader In Human Antibody Generation, For $178 Million In Cash And Stock

Ligand To Acquire OMT, Inc., A Leader In Human Antibody Generation, For $178 Million In Cash And Stock

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and OMT, Inc.

RODES Signs Exclusive Captisol® Licensing Agreement With Ligand Pharmaceuticals For Three Programs

RODES Signs Exclusive Captisol® Licensing Agreement With Ligand Pharmaceuticals For Three Programs

RODES, Inc. and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announce the signing of exclusive global license and supply agreements for three Captisol-enabled™ (CE) programs.

Ligand Pharmaceuticals (LGND) Stock Has the Right Medicine

Ligand Pharmaceuticals (LGND) Stock Has the Right Medicine

Buy LGND at current levels and add to longs on a close above $110.

Stock To Watch: Ligand Pharmaceuticals (LGND) In Perilous Reversal

Stock To Watch: Ligand Pharmaceuticals (LGND) In Perilous Reversal

Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a "perilous reversal" (up big yesterday but down big today) candidate

Ligand Provides Highlights From Today's Analyst Day Event

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered...

Ligand Reports Third Quarter 2015 Financial Results

Ligand Reports Third Quarter 2015 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2015, and provided an operating forecast and program updates.

Ligand Pharmaceuticals (LGND) Marked As A Dead Cat Bounce Stock

Ligand Pharmaceuticals (LGND) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a "dead cat bounce" (down big yesterday but up big today) candidate